|1.||Schally, Andrew V: 9 articles (02/2013 - 08/2002)|
|2.||Varga, Jozsef L: 8 articles (08/2006 - 08/2002)|
|3.||Groot, Kate: 5 articles (03/2006 - 08/2002)|
|4.||Schally, A V: 5 articles (02/2004 - 07/2000)|
|5.||Varga, J L: 5 articles (02/2004 - 07/2000)|
|6.||Armatis, Patricia: 4 articles (03/2006 - 09/2002)|
|7.||Busto, Rebeca: 4 articles (11/2003 - 08/2002)|
|8.||Halmos, Gabor: 3 articles (08/2006 - 11/2003)|
|9.||Letsch, Markus: 3 articles (03/2006 - 08/2002)|
|10.||Groot, K: 3 articles (02/2004 - 07/2000)|
|1.||Prostatic Neoplasms (Prostate Cancer)
03/01/2005 - "JV-1-38 evoked prompt Ca2+ signal in a dose-dependent way (1-10 microM) and induced early stage of apoptosis in LNCaP human prostate cancer cells at a concentration effective in suppression of cell proliferation (10 microM) peaking after 3 h. "
03/01/2005 - "We used flow cytometry to investigate whether GHRH antagonist JV-1-38 can induce changes in the cytosolic free Ca2+ concentration leading to apoptosis in LNCaP human prostate cancer cells. "
03/21/2006 - "GHRH antagonist MZ-J-7-114 (5 mug/day) significantly suppressed the growth of PC-3 human androgen-independent prostate cancers xenografted into nude mice and reduced serum IGF-I levels, whereas antagonist JV-1-38 had no effect at the dose of 10 mug/day. "
08/01/2002 - "Nevertheless, the stronger inhibition of tumor growth after combined treatment with JV-1-38 and RC-160 indicates that the interference with multiple local stimulatory factors leads to an enhanced inhibition of prostate cancer."
08/01/2002 - "To shed more light on the mechanisms involved, the effects of JV-1-38 on PC-3 human prostate cancer were compared with those of somatostatin analog RC-160 in vivo and in vitro. "
|2.||Neoplasm Metastasis (Metastasis)
09/12/2000 - "In this study, GHRH antagonist JV-1-38 (20 microgram/day per animal s.c.) inhibited the growth of orthotopic CAKI-1 human renal cell carcinoma (RCC) by 83% and inhibited the development of metastases to lung and lymph nodes. "
02/15/2013 - "This study determined the effect of growth hormone-releasing hormone (GHRH) antagonists, JMR-132 and JV-1-38 on growth of PC3 tumors as well as on angiogenesis and metastasis through the evaluation of various factors that contribute largely to the progression of prostate cancer. "
11/15/2003 - "Treatment with GH-RH antagonist JV-1-38 significantly (P < 0.05-0.001) inhibited tumor growth as demonstrated by a 58% decrease in final tumor volume, 54% reduction in tumor weight, and the extension of tumor-doubling time from 8.5 +/- 1.38 to 12 +/- 1.07 days as compared with controls. "
02/04/2003 - "However, in androgen-independent DU-145 cancers, JV-1-38 alone could inhibit tumor growth by 57% (P < 0.05) after 45 days. "
02/04/2003 - "Thus, in castrated animals bearing MDA-PCa-2b cancers, the administration of JV-1-38 for 35 days virtually arrested tumor growth (94% inhibition vs. intact control, P < 0.01; and 75% vs. castrated control, P < 0.05). "
09/03/2002 - "The stimulation of some gastroenteropancreatic cancer cells by GHRH was followed by an increase in cAMP production, and GHRH antagonist JV-1-38 competitively inhibited this effect. "
02/04/2003 - "The growth of LNCaP tumors was also powerfully suppressed by JV-1-38 combined with castration (83% inhibition vs. intact control, P < 0.01; and 68% vs. castrated control, P < 0.05). "
|4.||Stomach Neoplasms (Stomach Cancer)
|5.||Osteosarcoma (Osteogenic Sarcoma)
10/15/2002 - "In this study, the authors investigated the effects of the GH-RH antagonist JV-1-38 on MNNG/HOS human osteosarcoma and SK-ES-1 human Ewing sarcoma cell lines. "
10/15/2002 - "In vitro, the proliferation of SK-ES-1 and MNNG/HOS cells was inhibited by JV-1-38 and by antisera to IGF-I and IGF-II. The inhibition of MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma by GH-RH antagonists was linked to a suppression of IGF-II production in tumors. "
|1.||Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)
|4.||Gonadotropin-Releasing Hormone (GnRH)
|7.||PhAcTyr(1)- Arg(2)- P(H)e(4- CL)(6)- Ala(8)- Tyr(Me)(10)- His(11)- Abu(15)- His(20)- Nle(27)- Arg(28)- HLCr(29)- GHRH(1-29)NH2
|8.||Insulin-Like Growth Factor I (IGF-1)
|9.||Messenger RNA (mRNA)
|10.||Insulin-Like Growth Factor II (Somatomedin A)
|2.||Heterologous Transplantation (Xenotransplantation)